Cardiometabolic Profile Related to Body Adiposity Identifies Patients Eligible for Bariatric Surgery More Accurately than BMI

Obesity Surgery

Volumn 25, Issue 9, 2015, Pages 1594-1603

  Gómez Ambrosi, Javier ^a,b,c   Moncada, Rafael ^a,c   Valentí, Víctor ^a,b,c   Silva, Camilo ^a,b,c   Ramírez, Beatriz ^a,b,c   Catalán, Victoria ^a,b,c   Rodríguez, Amaia ^a,b,c   Andrada, Patricia ^a   Escalada, Javier ^a,b   Pastor, Carlos ^a   Cienfuegos, Javier A ^a,b   Gil, María J ^a,b,c   Salvador, Javier ^a,b   Frühbeck, Gema ^a,b,c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Recinto de Complejo Hospitalario de Navarra   (Spain)

Author keywords

Adiposity; Bariatric surgery; BMI; Cardiometabolic risk; Eligibility criteria; HbA1c; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; BODY FAT; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PATIENT IDENTIFICATION; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; BLOOD; LIVER FUNCTION TEST; OBESITY; PATIENT SELECTION;

ADIPOSITY; ADULT; BARIATRIC SURGERY; BODY MASS INDEX; C-REACTIVE PROTEIN; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PATIENT SELECTION; TRIGLYCERIDES; URIC ACID;

EID: 84938423596     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-014-1566-6     Document Type: Article

References (48)

1. Frühbeck G, Toplak H, Woodward E, et al. Obesity: the gateway to ill health—an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6:117–20.
2. Frühbeck G, Gómez-Ambrosi J. Control of body weight: a physiologic and transgenic perspective. Diabetologia. 2003;46:143–72.
3. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–83.
4. Apovian CM, Gokce N. Obesity and cardiovascular disease. Circulation. 2012;125:1178–82.
5. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–25 e6.
6. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014;383:736–47.
7. Campo A, Frühbeck G, Zulueta JJ, et al. Hyperleptinaemia, respiratory drive and hypercapnic response in obese patients. Eur Respir J. 2007;30:223–31.
8. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Adipose tissue immunity and cancer. Front Physiol. 2013;4:275.
9. Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755–65.
10. Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev. 2011;12:131–41.
11. Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370:233–44.
12. Frühbeck G, Gómez Ambrosi J, Salvador J. Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J. 2001;15:333–40.
13. Frühbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol Biol. 2008;456:1–22.
14. Poulain-Godefroy O, Lecoeur C, Pattou F, et al. Inflammation is associated with a decrease of lipogenic factors in omental fat in women. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1–7.
15. Vest AR, Heneghan HM, Schauer PR, et al. Surgical management of obesity and the relationship to cardiovascular disease. Circulation. 2013;127:945–59.
16. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.
17. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.
18. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.
19. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13.
20. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65.
21. Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. A systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg. 2011;253:484–7.
22. Neff KJ, le Roux CW. Bariatric surgery: a best practice article. J Clin Pathol. 2013;66:90–8.
23. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American association of clinical endocrinologists, the obesity society, and American society for metabolic & bariatric surgery. Obesity. 2013;21 Suppl 1:S1–27.
24. Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg. 2014;24:42–55.
25. Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. Obesity. 2011;19:1439–44.
26. Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes. 2012;36:286–94.
27. Gómez-Ambrosi J, Silva C, Catalán V, et al. Clinical usefulness of a new equation for estimating body fat. Diabetes Care. 2012;35:383–8.
28. Blundell JE, Dulloo AG, Salvador J, et al. Beyond BMI—phenotyping the obesities. Obes Facts. 2014;7:322–8.
29. Frühbeck G. Obesity: screening for the evident in obesity. Nat Rev Endocrinol. 2012;8:570–2.
30. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr. 1992;55:615S-9S.
31. Gómez-Ambrosi J, Salvador J, Rotellar F, et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg. 2006;16:262–9.
32. Muruzábal FJ, Frühbeck G, Gómez-Ambrosi J, et al. Immunocytochemical detection of leptin in non-mammalian vertebrate stomach. Gen Comp Endocrinol. 2002;128:149–52.
33. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018–22.
34. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865–72.
35. Prentice AM, Jebb SA. Beyond body mass index. Obes Rev. 2001;2:141–7.
36. Gómez-Ambrosi J, Salvador J, Frühbeck G. Letter by Gómez-Ambrosi et al. regarding article, “Clinical assessment and management of adult obesity”. Circulation. 2013;128:e39.
37. Gómez-Ambrosi J, Catalán V, Rodríguez A, et al. Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans. J Nutr Biochem. 2010;21:774–80.
38. Frige F, Laneri M, Veronelli A, et al. Bariatric surgery in obesity: changes of glucose and lipid metabolism correlate with changes of fat mass. Nutr Metab Cardiovasc Dis. 2009;19:198–204.
39. Sjöström L. Review of the key results from the Swedish obese subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34.
40. Miras AD, le Roux CW. Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. Lancet Diabetes Endocrinol. 2014;2:141–51.
41. Gómez-Ambrosi J, Pastor C, Salvador J, et al. Influence of waist circumference on the metabolic risk associated with impaired fasting glucose: effect of weight loss after gastric bypass. Obes Surg. 2007;17:585–91.
42. Cummings DE. Metabolic surgery for type 2 diabetes. Nat Med. 2012;18:656–8.
43. 2. Diabetes Obes Metab. 2012;14:262–70.
44. Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420–8.
45. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: Analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36:2175–82.
46. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240–9.
47. Sjöholm K, Anveden A, Peltonen M, et al. Evaluation of current eligibility criteria for bariatric surgery: diabetes prevention and risk factor changes in the Swedish obese subjects (SOS) study. Diabetes Care. 2013;36:1335–40.
48. Expert WHO. Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.